Source study found

Story checked

Could Type 2 Diabetes Be Reversed? 14-Year Study Reveals Remarkable Results (opens in a new tab)

scitechdaily.com · 2026-11-06

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

5 supported
1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail

The story

Could Type 2 Diabetes Be Reversed? 14-Year Study Reveals Remarkable Results

scitechdaily.com · 2026-11-06

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

One claim overstates the study. Five of six check out.

5 supported
1 overstated

Open claim evidence

The source study

Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study

Diabetes Care · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedGreater weight loss during the first year after treatment was associated with a higher likelihood of remission, and among people who initially reached remission, relapse was more likely in those with longer diabetes duration and more pre-treatment diabetes medications.View evidenceHide evidence

Why this verdict

The first part is supported: 1-year weight loss was associated with remission and selected in multivariable remission modeling. The relapse part is directionally consistent but overbroad as stated: the abstract reports relapse predictors specifically among MBS recipients who initially remitted, not among all participants who initially reached remission. The abstract also lacks relapse effect sizes and detailed relapse criteria.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Study evidence

Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used.

Claim 2 of 6SupportedIn a long-term trial, weight-loss surgery led to more type 2 diabetes remissions than intensive medical and lifestyle management.View evidenceHide evidence

As statedmore remissions

Why this verdict

The abstract reports a long-term ARMMS-T2D follow-up of participants previously randomized to metabolic-bariatric surgery versus medical-lifestyle management, with 58% of MBS-assigned participants achieving remission versus 3% in the medical-lifestyle group. The headline-style causal wording is acceptable at this depth because the comparison is between randomized assignment groups, though the paper profile frames the specific analytic work mainly as long-term prognostic/predictor modeling.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Claim 3 of 6SupportedA long-term study found that 58% of participants assigned to weight-loss surgery achieved remission during follow-up, compared with 3% of those assigned to intensive medical and lifestyle management.View evidenceHide evidence

As stated58% vs 3%

Why this verdict

The stated 58% versus 3% remission figures match the abstract exactly: throughout median 11 years of follow-up, 58% randomized to MBS achieved remission versus 3% randomized to medical-lifestyle management.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Claim 4 of 6SupportedParticipants were followed for a median of 11 years, with some followed for up to 14 years.View evidenceHide evidence

As statedmedian 11 years; up to 14 years

Why this verdict

The abstract-level profile states follow-up was a median of 11 years with a maximum of 14 years.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Study evidence

Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used.

Claim 5 of 6SupportedThe study defined remission as an A1C below 6.5% without blood sugar-lowering medication.View evidenceHide evidence

As statedA1C below 6.5% without medication

Why this verdict

The remission definition matches the paper profile: HbA1c/A1C below 6.5% while off glucose-lowering medications.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Study evidence

Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used.

Claim 6 of 6SupportedPeople with fewer years of diabetes, no insulin use, and fewer types of blood sugar-lowering medications before treatment were more likely to achieve remission.View evidenceHide evidence

Why this verdict

The abstract reports that shorter diabetes duration, no insulin use, and fewer glucose-lowering medication classes were predictors of remission in univariate analyses. Baseline diabetes duration and insulin use were also selected in multivariable LASSO models. The story’s general associational phrasing is consistent, though it does not distinguish univariate from multivariable findings.

Study evidence

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Other univariate remission predictors included greater body weight and higher fasting C-peptide and insulin.
These abstract-reported predictors are not reflected in the story claims provided.
From Post-randomization longitudinal prognostic analysis of ARMMS-T2D cohort
Relapse predictors were reported for the MBS subgroup after initial remission: longer baseline diabetes duration and more glucose-lowering medication classes predicted relapse.
The story reflects the direction of the relapse predictors but omits the important scope restriction that this relapse analysis was reported among MBS-treated participants who initially remitted.
From Randomized trial cohort with long-term observational subgroup/time-to-event analysis

6 things the story did carry across

Study design and population: ARMMS-T2D long-term multicenter follow-up of 262 adults with type 2 diabetes previously randomized to MBS or medical-lifestyle management.
Primary remission comparison: 58% of participants randomized to MBS achieved remission during follow-up versus 3% randomized to medical-lifestyle management.
Important interpretation of remission percentage: the 58% and 3% figures describe ever achieving remission during follow-up, not remaining continuously in remission for the entire follow-up period.
Follow-up duration: median 11 years and maximum 14 years.
Remission outcome definition: HbA1c/A1C <6.5% without glucose-lowering medications.
Remission predictors: shorter diabetes duration, no insulin use, fewer glucose-lowering medication classes, and 1-year weight loss were associated with remission; multivariable LASSO selected diabetes duration, insulin use, and 1-year weight change.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoIdentify baseline patient characteristics that predict long-term type 2 diabetes remission after metabolic-bariatric surgery (MBS) versus intensive medical-lifestyle therapy in the ARMMS-T2D cohort.Post-randomization longitudinal prognostic analysis of ARMMS-T2D cohortExpand

In plain English

In the ARMMS-T2D multicenter cohort (n=262) of adults with type 2 diabetes previously randomized to metabolic-bariatric surgery (MBS, n=166) versus medical-lifestyle management (n=96) and followed for a median of 11 years (max 14), investigators evaluated baseline predictors of diabetes remission (HbA1c <6.5% off glucose-lowering medications) using univariate time-to-event screening of prespecified candidates and an agnostic multivariable LASSO approach. Overall remission occurred in 58% of participants randomized to MBS versus 3% randomized to medical-lifestyle. Univariate predictors of remission included shorter diabetes duration, no insulin use, fewer medication classes, greater body weight, higher fasting C‑peptide and insulin, and 1-year weight loss. In multivariable (LASSO) models, baseline diabetes duration, insulin use, and weight change at 1 year predicted remission (all P < 0.01). Among MBS recipients who initially remitted, relapse was predicted by longer baseline diabetes duration and a greater number of glucose-lowering medication classes.

Key findings

Remission rates over median 11 years: 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management.58% vs 3%
Univariate time-to-event analyses identified shorter diabetes duration, no insulin use, fewer glucose-lowering medication classes, greater body weight, higher fasting C-peptide and insulin, and weight loss at 1 year as predictors of diabetes remission.

What this piece can’t prove

2 further details could not be confirmed from the summary.

2human in vivoIdentify predictors of diabetes relapse after an initial remission, particularly within the MBS-treated participants.Randomized trial cohort with long-term observational subgroup/time-to-event analysisExpand

In plain English

In the ARMMS-T2D cohort, diabetes relapse after an initial remission among participants randomized to metabolic-bariatric surgery (MBS) was predicted by longer baseline diabetes duration and a greater number of glucose-lowering medication classes used. Relapse was analyzed as a time-to-event outcome among those who initially achieved remission, using univariate time-to-event screening and an agnostic multivariable (LASSO) approach.

Key findings

Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used.

What this piece can’t prove

The abstract does not define the precise operational criteria for relapse (e.g., HbA1c threshold or medication restart), limiting interpretation of the outcome.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer